Detection of HPV E6 oncoprotein from urine via a novel immunochromatographic assay

• DOI: 10.1371/journal.pone.0232105
• Publication Date: 2020-04-22T17:33:07Z
• Authors: Cristina Mendes d...; Laura W. Musselwhite; Naitielle de Paul...; Fabiana Lima Vazquez; Jennifer S. Smith; Johannes Schweizer; Michael Belmares; Júlio César Possa...; Marcelo de Andrad...; Adhemar Longatto-...; José Humberto Tav...
• Keywords: Concordance; Cervical screening

Cervical cancer is a significant public health problem, especially in low- and middle-income countries, where women have little access to cervical screening; consequently 80% of related mortality occurs these regions. The development screening methods that need less infrastructure thus represents an urgent medical need. study aims compare the detection rates high-risk human papillomavirus 16 18 E6 oncoprotein urine, vaginal self-collected, scrapes using OncoE6™ Test HPV16 and/or HPV18 with HPV DNA testing. Paired self-collected specimens were collected from 124 who participated or treatment this proof-of-concept underwent HPV16/18-E6 testing prior neoplasia cancer. Concordance between urinary, HPV-DNA was evaluated for patients classified as negative group (<CIN2) histological positive (CIN2, CIN3 invasive carcinoma). Overall, detected 30.6% samples, 20.3% samples 21% urine samples. Regarding clinical sensitivity, not CIN2 cases, at low cases. sensitivity detecting 70% scrapes, 55% 52% This reports urinary vivo first time our results suggest only invasive/microinvasive lesions. Then, further protocol standardization achieve CIN2/3 close what can be achieved lesions physician needed.